Bicycle Therapeutics plc

Bicycle Therapeutics plc is a clinical-stage pharmaceutical company that develops a novel class of medicines called Bicycles, which are synthetic, short peptides constrained to form a stable, bicyclic structure. These molecules combine the properties of small molecules and biologics to target diseases underserved by existing therapies. The company's lead product candidate is zelenectide pevedotin, a Bicycle toxin conjugate (BTC) targeting nectin-4, currently in Phase II trials for high nectin-4 expressing tumors. Other pipeline assets include nuzefatide pevedotin (EphA2) in Phase I/II, BT7480 (a Bicycle tumor-targeted immune cell agonist targeting nectin-4 and CD137) in Phase I/II, and BT1702, a theranostic BRC molecule targeting MT1-MMP. Preclinical programs target CNS diseases, neuromuscular diseases, and radiopharmaceuticals. Bicycle also collaborates with partners such as Bayer, Novartis, Ionis, Genentech, and AstraZeneca.

Bicycle Therapeutics plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BCYC. The trading currency is the US Dollar (USD). As a company headquartered in the United Kingdom, its shares trade on a US exchange, making it accessible to international investors. The listing on Nasdaq provides liquidity and exposure to a broad investor base in the US capital markets.

Bicycle Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotech company, it focuses on discovering and developing innovative therapies for diseases with high unmet medical need. The biotechnology industry is characterized by intensive research and development, regulatory milestones, and potential for breakthrough treatments. Bicycle's unique Bicycle platform differentiates it from traditional biologics and small molecule approaches, targeting both oncology and other therapeutic areas.

Bicycle Therapeutics plc is headquartered in Cambridge, United Kingdom, and was incorporated in 2009. The company primarily serves the United States and United Kingdom markets, as indicated by its clinical operations and collaborations. Its pipeline targets patients with various cancers and other diseases, with clinical trials conducted in both regions. The company also has collaboration agreements with global pharmaceutical partners, extending its reach to broader international markets through licensing and joint development efforts.

As a clinical-stage company, Bicycle Therapeutics does not yet have approved products generating commercial revenue. Its business model relies on advancing its proprietary Bicycle platform through clinical development and forming strategic collaborations with larger pharmaceutical companies. The company has entered into collaboration and license agreements with Bayer Consumer Care AG, Novartis Pharma AG, Ionis Pharmaceuticals, Inc., Genentech, Inc., and AstraZeneca AB. These partnerships typically involve upfront payments, milestone payments, and royalties on future product sales. Bicycle also progresses its own pipeline candidates, such as zelenectide pevedotin and BT7480, with the goal of eventually commercializing them independently or through partnerships.